Our founder, George Schlich, has a degree in Natural Sciences from Cambridge University, UK, specialising in biology of cells, chemistry, pathology, physiology, mathematics, pharmacology, and history and philosophy of science.
Highly regarded in the profession, George is listed as “recommended” in IAM1000 2022, who say that George’s “sensible and practical approach helps clients better understand the intricacies of patent protection”. Further noted is that George is “well versed in CRISPR” due to the fact that he “has recently undertaken a raft of related oppositions at the EPO”. George started his career with a mixture of small molecule chemistry from US pharmaceutical companies and, closer to home, stem cell inventions from the University of Edinburgh, UK and missile guidance systems from the defence industry.
This early experience has been expanded and built on over the years. Since then, George has advised start-up companies as well as small to medium to major corporate clients in Europe and the US across the gamut of their IP interests, supporting flotations on London’s AIM market. Today, George has developed considerable experience in the protection of inventions, via patents, designs, and trade marks, in areas from stem cells to breakfast cereals, from recombinant proteins to vaccines and from inhalation pharmaceuticals to cathode arc deposition of thin films.
He specialises in patents in the chemical and biochemical fields and also advises on trade marks and designs. In relation to CRISPR/Cas9, George represents Intellia Therapeutics, Inc. George specialises in representing patent owners and opponents at inter-partes hearings before the European Patent Office (EPO), the UK Patent Office, and has extensive experience of Opposition and Appeals, meriting an entry in the UK’s “Legal 500”.Get in touch today